<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26487" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Oxybutynin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dwyer</surname>
            <given-names>Jennifer</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tafuri</surname>
            <given-names>Sean M.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>LaGrange</surname>
            <given-names>Chad A.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Dwyer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sean Tafuri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chad LaGrange declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26487.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Oxybutynin, an anticholinergic medication, is approved by the U.S. Food and Drug Administration (FDA) and is indicated for patients with overactive bladder or symptoms of detrusor overactivity, such as urinary frequency and urgency.&#x000a0;Oxybutynin works through competitive acetylcholine antagonism at postganglionic muscarinic receptors, leading to the relaxation of the smooth muscles of the bladder.&#x000a0;This medication has been thoroughly researched and approved for use in patients aged 5 and older. In addition,&#x000a0;oxybutynin is recommended for individuals who experience detrusor instability due to neurogenic bladder.&#x000a0;In certain cases, oxybutynin may be used to control&#x000a0;bladder spasms triggered by indwelling ureteral stents or Foley catheters. This activity provides a comprehensive overview of oxybutynin's indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity.&#x000a0;The activity also aims to equip the interprofessional healthcare team by enhancing their competence&#x000a0;to direct patient therapy effectively, particularly when anticholinergic treatment is warranted for patients with overactive bladder.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients who may benefit from oxybutynin therapy based on appropriate indications, such as overactive bladder, urinary incontinence, or neurogenic bladder.</p></list-item><list-item><p>Screen patients for contraindications and potential drug interactions before initiating oxybutynin therapy, considering factors such as glaucoma, urinary retention, and hypersensitivity reactions.</p></list-item><list-item><p>Assess the effectiveness of oxybutynin therapy in managing bladder-related symptoms by monitoring changes in urinary frequency, urgency, and incontinence episodes.</p></list-item><list-item><p>Coordinate with patients' primary care providers and healthcare team members to monitor the overall treatment plan and make necessary adjustments, promoting optimal bladder health and quality of life.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26487&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26487">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26487.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Oxybutynin, an anticholinergic medication, is approved by the U.S. Food and Drug Administration (FDA) and is indicated for patients with overactive bladder or symptoms of detrusor overactivity, such as urinary frequency and urgency. Animal studies have demonstrated that&#x000a0;the medication&#x000a0;possesses an antispasmodic effect that is 4&#x000a0;to 10 times stronger than&#x000a0;atropine. Oxybutynin is also indicated for patients with detrusor instability associated with neurogenic bladder conditions, such as spina bifida.&#x000a0;This medication has been thoroughly researched and approved for use in patients aged 5 and older.<xref ref-type="bibr" rid="article-26487.r1">[1]</xref><xref ref-type="bibr" rid="article-26487.r2">[2]</xref></p>
        <p>
<bold>Off-Labeled Indications</bold>
</p>
        <p>In some instances, oxybutynin can be utilized to control bladder spasms caused by indwelling ureteral stents or Foley catheters. However, this particular usage has not been approved by the FDA.<xref ref-type="bibr" rid="article-26487.r3">[3]</xref> Oxybutynin is combined with desmopressin to address refractory nocturnal enuresis.<xref ref-type="bibr" rid="article-26487.r4">[4]</xref>&#x000a0;In addition, this drug finds utility in treating primary focal hyperhidrosis.<xref ref-type="bibr" rid="article-26487.r5">[5]</xref><bold>&#x000a0;</bold></p>
        <p>According to a case report, oxybutynin appears effective in managing methadone-induced hyperhidrosis. Furthermore, another case report outlines the successful utilization of oxybutynin to manage hyperhidrosis associated with buprenorphine or naloxone therapy for opioid withdrawal.<xref ref-type="bibr" rid="article-26487.r6">[6]</xref><xref ref-type="bibr" rid="article-26487.r7">[7]</xref> Investigations are underway for topical formulations of oxybutynin to address hyperhidrosis while minimizing systemic adverse effects.<xref ref-type="bibr" rid="article-26487.r8">[8]</xref></p>
      </sec>
      <sec id="article-26487.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Oxybutynin is classified as an anticholinergic drug that acts as an antispasmodic against smooth muscle, particularly in the bladder. The active metabolite of oxybutynin is <italic toggle="yes">N</italic>-desethyloxybutynin.<xref ref-type="bibr" rid="article-26487.r9">[9]</xref>&#x000a0;This medication competitively inhibits the postganglionic muscarinic 1, 2, and 3 receptors, thereby blocking the muscarinic effect of acetylcholine and leading to the relaxation of the bladder smooth muscles of the bladder. As a result, oxybutynin increases bladder capacity and reduces urinary urgency and frequency. Oxybutynin also&#x000a0;has been shown to delay the initial desire to void.<xref ref-type="bibr" rid="article-26487.r10">[10]</xref><xref ref-type="bibr" rid="article-26487.r11">[11]</xref>&#x000a0;</p>
        <p>Oxybutynin acts by competitive acetylcholine antagonism at postganglionic muscarinic receptors, which results in the relaxation of the smooth muscles of the bladder. The FDA has approved several dosage forms of oxybutynin, including oral immediate-release and extended-release tablets, topical gel, and transdermal patches. Oxybutynin is available for intravesical instillation and as a rectal suppository. Moreover, there is ongoing development of vaginal preparation. Each formulation has different efficacy and adverse-event profiles.<xref ref-type="bibr" rid="article-26487.r12">[12]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption: Oxybutynin is rapidly absorbed by the body after the oral administration of oxybutynin chloride immediate-release tablets, with an absolute bioavailability of approximately 6% (ranging between 1.6% and 10.9%). The drug reaches its maximum plasma concentration (Cmax) within 1 hour and exhibits a plasma half-life of approximately 2 to 3 hours. Clinical data in the literature indicates that oxybutynin solution exhibits a slightly delayed absorption when co-administered with food, resulting in increased bioavailability of approximately 25%.&#x000a0;</p>
        <p>Distribution: Oxybutynin demonstrates a substantial volume of distribution, measuring 193 L, following the intravenous administration of 5 mg oxybutynin chloride. Furthermore, both enantiomers of oxybutynin (<italic toggle="yes">R</italic> and <italic toggle="yes">S</italic>) exhibit a high protein binding rate of 99%.&#x000a0;This drug&#x000a0;can cross the blood-brain barrier, possibly impairing cognitive function.<xref ref-type="bibr" rid="article-26487.r13">[13]</xref><xref ref-type="bibr" rid="article-26487.r14">[14]</xref></p>
        <p>Metabolism: Oxybutynin is primarily metabolized by the cytochrome P450 enzyme systems, mainly processed by CYP3A4 in the liver.&#x000a0;The metabolism of oxybutynin produces 2 metabolites, including phenyl cyclohexyl glycolic acid and&#x000a0;desethyloxybutynin. The first substance, phenyl cyclohexyl glycolic acid, is inactive, whereas the second substance, desethyloxybutynin, has pharmacological activity.<xref ref-type="bibr" rid="article-26487.r15">[15]</xref></p>
        <p>Excretion: Oxybutynin is primarily metabolized in the liver, with less than 0.1% of the administered dose excreted unchanged in the urine and less than 0.1% excreted as the desethyloxybutynin metabolite.</p>
      </sec>
      <sec id="article-26487.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Various formulations and routes of administration are available for oxybutynin, offering different options to help patients manage their overactive bladder or related issues. The most common choices include oral administration of the drug in the form of pills or tablets, which can be either immediate-release or&#x000a0;extended-release formulations. The initial dosage for both formulations of oxybutynin starts at 5 mg. In addition, the medication can also be administered to patients in the form of a syrup, transdermal patch, or gel.&#x000a0;Oxybutynin syrup is available in 16-ounce containers and is formulated as&#x000a0;1 mg/mL. Notably, both the immediate-release and the extended-release tablets have the same starting and maximum doses.</p>
        <p>The long-acting or extended-release oxybutynin tablets are available in strengths of 5 mg, 10 mg, or 15 mg of oxybutynin chloride. This formulation is designed as a once-daily oral medication and employs an osmotic pressure delivery system to release the drug over a period of 24 hours gradually. The oral forms of oxybutynin are absorbed similarly, regardless of whether the patient is in the fed or fasted state.</p>
        <p>The oxybutynin transdermal system or patch provides continuous medication delivery for 3 to 4 days following its application. The patch contains 36 mg of oxybutynin, resulting in an average daily absorbed dose of 3.9 mg. The steady-state concentrations of the drug are achieved during the second application of the patch. The oxybutynin patch should be applied to a patient's abdomen, buttock, or hip. To ensure safety, patients should refrain from reapplying the transdermal patch to the same site within 7 days of applying it.&#x000a0;Notably,&#x000a0;the safety of this medication has not been established in pediatric patients.</p>
        <p>The oxybutynin gel (10%) is supplied in sachets, and to use the medication, the contents of 1&#x000a0;sachet should be opened and applied onto clean, dry, and unbroken skin on the abdomen, upper arms, or thighs. The steady-state concentrations of the drug are achieved within 7 days of continuous medication dosing. Application sites of the drug should be rotated to avoid irritation or skin problems. The safety of&#x000a0;oxybutynin&#x000a0;has not been established in pediatric patients.</p>
        <p>Various treatment options are available for patients experiencing overactive bladder or related issues, including medications such as oxybutynin, behavioral therapies, and lifestyle changes. These treatments can help patients to manage their symptoms and enhance their comfort and overall well-being. Below is the recommended dosage chart for oxybutynin across all age groups.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Here is the list of the recommended oxybutynin dosages for adults:</p>
        <list list-type="bullet">
          <list-item>
            <p>The starting dosage for immediate-release oxybutynin is a 5 mg tablet to be administered 2 to 3 times daily. Physicians advise that the daily intake of oxybutynin 5 mg tablets should not exceed 4 tablets per day for adults.</p>
          </list-item>
          <list-item>
            <p>The&#x000a0;initial dosage for extended-release oxybutynin is a 5 mg tablet administered once daily, and&#x000a0;the drug should be taken at the same time every day. The daily dose of the medication can be raised by 5 mg, with a maximum limit of up to 30 mg.</p>
          </list-item>
          <list-item>
            <p>For the topical gel formulation, the content of 1 pump actuation or 1 sachet of oxybutynin should be applied daily to&#x000a0;the affected area as directed by the physician.</p>
          </list-item>
          <list-item>
            <p>For the transdermal patch, a 3.9 mg patch&#x000a0;of&#x000a0;oxybutynin should be applied twice weekly. Before using a new patch on the same area for 2 days each week, the old patch should be removed to ensure proper dosing and efficacy of the medication. Patients can use a 3.9 mg oxybutynin patch every fourth day as an over-the-counter product.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Geriatric patients: As per the American Geriatric Society (Beers Criteria), oxybutynin is considered a potentially inappropriate medication for older patients due to its anticholinergic adverse effects. Therefore,&#x000a0;oxybutynin should only be administered to older patients if the potential benefit outweighs the risks. Physicians&#x000a0;recommended starting oxybutynin treatment with a lower dosage of 2.5 mg administered 2 to 3&#x000a0;times daily for immediate release. This cautious approach is due to the prolonged elimination half-life of oxybutynin, which ranges from 2 to 3 hours and can extend up to 5 hours in older populations.<xref ref-type="bibr" rid="article-26487.r16">[16]</xref></p>
        <p>Pediatric patients:&#x000a0;The starting or maximum dosage recommended for pediatric patients aged 5 and older is a&#x000a0;5 mg tablet administered 2&#x000a0;to 3 times daily&#x000a0;for immediate release. The recommended starting dosage for&#x000a0;pediatric patients aged 6 and older is 5 mg of extended-release oxybutynin administered once daily. The maximum daily dosage for this group of pediatric population should not exceed 20 mg. The extended-release form of oxybutynin should not be administered to pediatric patients younger than 6 or those unable to swallow the tablet whole. The extended-release tablets&#x000a0;should not be chewed, crushed, or divided, as they are designed to release the medication gradually. In certain cases, oxybutynin is used as an off-label drug&#x000a0;to control overactive bladder in children&#x000a0;aged 1 to 5, with a dosing regimen of 0.2 mg/kg orally administered 2 to 4 times daily. The recommended maximum daily dosage for this group should not exceed 15 mg.</p>
        <p>Pregnancy considerations: In an observational study, the use of oxybutynin in pregnant patients with spinal cord injuries did not show any adverse effects on pregnancy outcomes. However, further research is necessary to fully assess the safety of oxybutynin use during pregnancy.<xref ref-type="bibr" rid="article-26487.r17">[17]</xref> Oxybutynin is classified as a category B medication for pregnant patients. Although&#x000a0;animal studies have not provided definitive evidence of harm to the fetus during pregnancy, conclusive safety data for this period have not been established yet. Oxybutynin should be prescribed in pregnancy only if the clinical benefits to the mother outweigh the potential risks to the fetus.<xref ref-type="bibr" rid="article-26487.r18">[18]</xref></p>
        <p>Breastfeeding considerations:&#x000a0;Currently, no evidence is available regarding the use of oxybutynin in nursing mothers.&#x000a0;In certain cases where breastfeeding women take oxybutynin for an extended period, it is recommended to&#x000a0;monitor their baby for any indications of reduced milk supply, such as slow weight gain or signs of in-satiety.<xref ref-type="bibr" rid="article-26487.r19">[19]</xref></p>
        <p>Primary focal hyperhidrosis: For individuals who have primary focal hyperhidrosis, a dosage of oxybutynin immediate-release formulation starting at 2.5 mg is administered once daily and adjusted gradually based on tolerance. The dosage of the medication can range from 5 to 10 mg daily, divided into 2&#x000a0; doses.<xref ref-type="bibr" rid="article-26487.r20">[20]</xref> The dosage for extended-release oxybutynin for this group of patients typically ranges from 5 to 10 mg, administered once daily.</p>
        <p>Refractory nocturnal enuresis: A&#x000a0;combination of&#x000a0;desmopressin and oxybutynin therapy is suggested as a treatment option for&#x000a0;pediatric patients with refractory nocturnal enuresis.&#x000a0;Combination therapy with desmopressin and oxybutynin is more effective than using desmopressin-only therapy. The initial dose of oxybutynin for this condition is 5 mg, with the maximum recommended dose being 10 mg.<xref ref-type="bibr" rid="article-26487.r4">[4]</xref><xref ref-type="bibr" rid="article-26487.r21">[21]</xref><xref ref-type="bibr" rid="article-26487.r22">[22]</xref></p>
        <p>Hepatic and renal impairment: Caution should be exercised while prescribing oxybutynin to patients with hepatic or renal impairment,&#x000a0;as the dosages allocated for these cases are not defined yet.</p>
      </sec>
      <sec id="article-26487.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The immediate-release form of oxybutynin can cause various adverse effects in patients, including dry mouth (71.4%), dizziness (16.6%), constipation (15.1%), somnolence (14.0%), and nausea (11.6%). Some of the less common adverse effects of immediate-release oxybutynin include blurred vision (9.6%), urinary hesitation (8.5%), urinary retention (6.0%), and dyspepsia (6.0%).&#x000a0;Notably, a dry mouth is considered a dose-related adverse effect of oxybutynin.<xref ref-type="bibr" rid="article-26487.r23">[23]</xref><xref ref-type="bibr" rid="article-26487.r24">[24]</xref>&#x000a0;Oxybutynin hydrochloride has a more favorable profile than other antimuscarinic drugs regarding adverse effects on heart rate increase.<xref ref-type="bibr" rid="article-26487.r25">[25]</xref></p>
        <p>Although the adverse effects caused by the&#x000a0;extended-release form of oxybutynin are similar to the immediate-release form, the rates of the&#x000a0;extended-release form have been reported as lower compared to the immediate-release form. These include dry mouth (29% to 61%), constipation (7% to 13%), somnolence (2% to 12%), headache (6% to 10%), diarrhea (7% to 9%), nausea (2% to 9%), blurred vision (1% to 8%) and dry eyes (3% to 6%). A dry mouth is considered a dose-related adverse effect of oxybutynin. The various adverse events led to the discontinuation of the medicine in 6.8% of patients.</p>
        <p>Application site reactions were reported in 5.4% of patients using oxybutynin gel and 16.8% using the oxybutynin transdermal system compared to 6.1% of patients in the placebo group. The signs of a dry mouth were less common in patients receiving transdermal oxybutynin than in the oral forms, with rates reported as 7.5% for the gel and 9.6% for the patch. Adverse effects of oxybutynin are often related to the dose of the medication. The oxybutynin-induced&#x000a0;brief psychotic disorder has been reported in the medical literature.<xref ref-type="bibr" rid="article-26487.r26">[26]</xref> Moreover, a recent case report documents oxybutynin overuse resulting in repeated delirious states and subsequent hospitalization of a patient.<xref ref-type="bibr" rid="article-26487.r27">[27]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CYP3A4 primarily metabolizes oxybutynin. Caution should be exercised when using potent CYP3A4 inhibitors, such as ketoconazole, as they may increase the plasma concentration of oxybutynin.<xref ref-type="bibr" rid="article-26487.r28">[28]</xref> Likewise, other inhibitors of the CYP3A4 enzyme, such as itraconazole, miconazole, clarithromycin, erythromycin, and grapefruit juice, have the potential to affect the plasma concentration of oxybutynin; therefore, concurrent use of these substances requires caution.<xref ref-type="bibr" rid="article-26487.r29">[29]</xref><xref ref-type="bibr" rid="article-26487.r30">[30]</xref><xref ref-type="bibr" rid="article-26487.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oxybutynin can decrease gut motility, which may reduce the effectiveness of prokinetic drugs, such as metoclopramide.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Caution should be exercised while using oxybutynin concurrently with other anticholinergic drugs, as they can lead to an increased risk of adverse effects, such as xerostomia (dry mouth), constipation, and urinary retention.<xref ref-type="bibr" rid="article-26487.r32">[32]</xref><bold/></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26487.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Oxybutynin is contraindicated in patients with urinary retention, bladder obstruction, poorly controlled narrow-angle glaucoma, obstructive gastric disorders, or gastric dysmotility. In addition,&#x000a0;oxybutynin should not be used in patients with hypersensitivity to the drug or its excipients. Angioedema of the face, tongue, lips, and larynx has been reported with oxybutynin use, necessitating the discontinuation of the medication and ensuring a patent airway to manage the condition promptly and effectively.<xref ref-type="bibr" rid="article-26487.r33">[33]</xref></p>
        <p>As recommended by physicians, caution should be exercised while&#x000a0;using oxybutynin for patients who are old,&#x000a0;diagnosed with myasthenia gravis, who have dementia and are being treated with cholinesterase inhibitors, with Parkinson disease, and with renal or hepatic impairments.</p>
        <p>The dose of the extended-release formulation needs to be reduced or discontinued if a patient experiences anticholinergic central nervous system adverse reactions to oxybutynin. In addition, in patients with autonomic neuropathy, the use of the extended-release formulation of oxybutynin should be approached with caution, as it may exacerbate symptoms of decreased gastric motility.<xref ref-type="bibr" rid="article-26487.r34">[34]</xref></p>
      </sec>
      <sec id="article-26487.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should be closely monitored for anticholinergic adverse effects related to the central nervous system, including hallucinations, agitation, confusion, and somnolence. This monitoring is&#x000a0;critical&#x000a0;for older patients and for patients during their initial few months of&#x000a0;oxybutynin treatment or after increasing the dosage of&#x000a0;the medication.</p>
        <p>Healthcare professionals should counsel patients that concomitant use of alcohol with oxybutynin may increase drowsiness, and&#x000a0;taking oxybutynin in a high-temperature environment can lead to heat prostration, which may manifest as fever and heat stroke due to reduced sweating.<xref ref-type="bibr" rid="article-26487.r35">[35]</xref>&#x000a0;Furthermore, administering&#x000a0;oxybutynin with other anticholinergic medications can increase the frequency and severity of the above-mentioned adverse effects.</p>
      </sec>
      <sec id="article-26487.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>If an overdose of oxybutynin is suspected, a medical professional should be sought for immediate care. Symptoms of oxybutynin overdose may include central nervous system overactivity, fever, cardiac arrhythmias, vomiting, respiratory failure, paralysis, and coma. The treatment for oxybutynin overdose typically involves supportive care from healthcare providers. In some cases, medical professionals may consider administering activated charcoal to patients to help absorb the excess medication in their digestive system. Alternatively, a cathartic agent might be used to promote bowel movements in patients to facilitate the elimination of the drug from the body.</p>
        <p>There have been 2 reported cases of drug overdose due to the consumption of 100 mg of oxybutynin: 1 case involved a 13-year-old boy, and the other case involved a 34-year-old woman. In addition, there was another report of simultaneous alcohol ingestion with the medication. In another case, a&#x000a0;4-year-old boy experienced a drug overdose and central anticholinergic syndrome after taking 17 mg of oxybutynin over 12 hours.<xref ref-type="bibr" rid="article-26487.r36">[36]</xref>&#x000a0;Patients in all the above cases&#x000a0;completely recovered after receiving supportive care from healthcare professionals. The controlled-release formulation of oxybutynin contains insoluble contents, which may result in the formation of bezoars.<xref ref-type="bibr" rid="article-26487.r37">[37]</xref></p>
      </sec>
      <sec id="article-26487.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals, including primary care physicians and advanced practice practitioners, who prescribe oxybutynin to patients, should be well-informed about its adverse effect profile. The adverse reactions of oxybutynin are often dosage-related. Patients should be monitored for anticholinergic adverse effects related to the central nervous system, which include hallucinations, agitation, confusion, and somnolence. These adverse reactions are&#x000a0;critical in older&#x000a0;patients and for patients during their initial few months of oxybutynin treatment or after increasing the dosage of the medication.</p>
        <p>Pharmacists&#x000a0;are critical in medication reconciliation and should counsel patients about the increased risk of drowsiness when using oxybutynin concurrently with alcohol. Moreover, patients should be informed that taking oxybutynin in a high-temperature environment may lead to heat prostration, manifesting as fever and heat stroke due to reduced sweating. Nursing staff should ensure the patient's comprehension of the medication and verify the correct dosage before administering oxybutynin. They should promptly report their observations and findings to the prescriber to ensure appropriate management of the condition. In cases of drug overdose or suspected toxicity, medical toxicologists should be consulted to provide expert guidance and assist in the patient's optimal care.</p>
        <p>Open communication and shared decision-making among interprofessional team members are essential in enhancing the efficacy and safety outcomes for patients undergoing oxybutynin treatment.</p>
      </sec>
      <sec id="article-26487.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26487&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26487">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26487/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26487">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26487.s11">
        <title>References</title>
        <ref id="article-26487.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hodson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Interventions for primary vesicoureteric reflux.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Feb</month>
            <day>20</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD001532</fpage>
            <pub-id pub-id-type="pmid">30784039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f6;fling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kieler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bahmanyar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer.</article-title>
            <source>Clin Epidemiol</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>133</fpage>
            <page-range>133-143</page-range>
            <pub-id pub-id-type="pmid">30774448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Coupe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Interventions for treating urinary incontinence after stroke in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD004462</fpage>
            <pub-id pub-id-type="pmid">30706461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;z&#x000fc;k&#x000fc;&#x000e7;&#x000fc;k</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x00131;l&#x00131;&#x000e7;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c7;ak&#x00131;ro&#x0011f;lu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Desmopressin versus desmopressin + oxybutynin in the treatment of children with nocturnal enuresis.</article-title>
            <source>J Pediatr Urol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>451.e1</fpage>
            <page-range>451.e1-451.e6</page-range>
            <pub-id pub-id-type="pmid">33931318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zur</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Topical Treatment of Primary Focal Hyperhidrosis, Part 1.</article-title>
            <source>Int J Pharm Compd</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-31</page-range>
            <pub-id pub-id-type="pmid">30668532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Totouom-Tangho</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Swift</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Methadone-Induced Hyperhidrosis Treated With Oxybutynin.</article-title>
            <source>J Addict Med</source>
            <year>2017</year>
            <season>May/Jun</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-238</page-range>
            <pub-id pub-id-type="pmid">28244893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCormack</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis.</article-title>
            <source>JAAD Case Rep</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>10</volume>
            <fpage>22</fpage>
            <page-range>22-24</page-range>
            <pub-id pub-id-type="pmid">33732840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Adlam</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Potts</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Farshchian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics.</article-title>
            <source>Dermatol Ther (Heidelb)</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>2705</fpage>
            <page-range>2705-2714</page-range>
            <pub-id pub-id-type="pmid">36329359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tian</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Simultaneous quantification of oxybutynin and its active metabolite N-desethyl oxybutynin in rat plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study of oxybutynin transdermal patch.</article-title>
            <source>Biomed Chromatogr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>e4456</fpage>
            <pub-id pub-id-type="pmid">30536598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hur</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ku</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bahk</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Comparative effectiveness of interventions for managing postoperative catheter-related bladder discomfort: a systematic review and network meta-analysis.</article-title>
            <source>J Anesth</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-208</page-range>
            <pub-id pub-id-type="pmid">30603826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herbison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Which anticholinergic is best for people with overactive bladders? A network meta-analysis.</article-title>
            <source>Neurourol Urodyn</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>525</fpage>
            <page-range>525-534</page-range>
            <pub-id pub-id-type="pmid">30575999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomelsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dmochowski</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin gel for the treatment of overactive bladder.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>1337</fpage>
            <page-range>1337-43</page-range>
            <pub-id pub-id-type="pmid">22607010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Araklitis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cardozo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.</article-title>
            <source>Clin Interv Aging</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>1493</fpage>
            <page-range>1493-1503</page-range>
            <pub-id pub-id-type="pmid">32921995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Tae</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Cognitive Function and Urologic Medications for Lower Urinary Tract Symptoms.</article-title>
            <source>Int Neurourol J</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-240</page-range>
            <pub-id pub-id-type="pmid">33017894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Oxybutynin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31643963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <collab>By the 2019 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2019 Updated AGS Beers Criteria&#x000ae; for Potentially Inappropriate Medication Use in Older Adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>67</volume>
            <issue>4</issue>
            <fpage>674</fpage>
            <page-range>674-694</page-range>
            <pub-id pub-id-type="pmid">30693946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andretta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landi</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cianfrocca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Manassero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Risi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Artuso</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Bladder management during pregnancy in women with spinal-cord injury: an observational, multicenter study.</article-title>
            <source>Int Urogynecol J</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-300</page-range>
            <pub-id pub-id-type="pmid">29600402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arisco</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Brantly</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin extended release for the management of overactive bladder: a clinical review.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2009</year>
            <month>Sep</month>
            <day>21</day>
            <volume>3</volume>
            <fpage>151</fpage>
            <page-range>151-61</page-range>
            <pub-id pub-id-type="pmid">19920931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Oxybutinyn</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30000728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schollhammer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brenaut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Menard-Andivot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pillette-Delarue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zagnoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chassain-Le Lay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sassolas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jouan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Ru</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abasq-Thomas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Penven</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roguedas-Contios</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dupr&#x000e9;-Goetghebeur</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gouedard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Misery</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le Gal</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.</article-title>
            <source>Br J Dermatol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>173</volume>
            <issue>5</issue>
            <fpage>1163</fpage>
            <page-range>1163-8</page-range>
            <pub-id pub-id-type="pmid">26114588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moorani</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Zehra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Comparative response of Desmopressin versus Combination Therapy (Desmopressin + Oxybutynin) in Children with Nocturnal Enuresis.</article-title>
            <source>Pak J Med Sci</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1263</fpage>
            <page-range>1263-1269</page-range>
            <pub-id pub-id-type="pmid">32968391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pires</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ellsworth</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Evaluating use of higher dose oxybutynin in combination with desmopressin for refractory nocturnal enuresis.</article-title>
            <source>J Pediatr Urol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>220.e1</fpage>
            <page-range>220.e1-6</page-range>
            <pub-id pub-id-type="pmid">27373215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vouri</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Schootman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Strope</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Xian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Antimuscarinic use and discontinuation in an older adult population.</article-title>
            <source>Arch Gerontol Geriatr</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>80</volume>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">30268971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vozmediano-Chicharro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Madurga</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blasco</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?</article-title>
            <source>Adv Urol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>6782736</fpage>
            <pub-id pub-id-type="pmid">30151004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cetinel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Onal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gultekin</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Guzelsoy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turegun</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Dincer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>417</fpage>
            <page-range>417-424</page-range>
            <pub-id pub-id-type="pmid">30725387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gulsun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sabanci</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Psychotic disorder induced by oxybutynin: Presentation of two cases.</article-title>
            <source>Clin Drug Investig</source>
            <year>2006</year>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>603</fpage>
            <page-range>603-6</page-range>
            <pub-id pub-id-type="pmid">17163294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marthi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pomerantz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mernan</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Berlow</surname>
                <given-names>YA</given-names>
              </name>
            </person-group>
            <article-title>The Twilight Zone: Oxybutynin Overuse Exacerbating Delirium.</article-title>
            <source>J Geriatr Psychiatry Neurol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>840</fpage>
            <page-range>840-845</page-range>
            <pub-id pub-id-type="pmid">35383492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bauters</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Clinically Relevant Drug Interactions in HSCT</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Carreras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mohty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kr&#x000f6;ger</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <source>The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]</source>
            <edition>7th</edition>
            <publisher-name>Springer</publisher-name>
            <publisher-loc>Cham (CH)</publisher-loc>
            <year>2019</year>
            <fpage>229</fpage>
            <lpage>235</lpage>
            <pub-id pub-id-type="pmid">32091802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahlinger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pietsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frechen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fuhr</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome.</article-title>
            <source>Ther Adv Urol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>163</fpage>
            <page-range>163-177</page-range>
            <pub-id pub-id-type="pmid">28747995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanger</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.</article-title>
            <source>Pharmacol Ther</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>138</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-41</page-range>
            <pub-id pub-id-type="pmid">23333322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loue</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tod</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data.</article-title>
            <source>AAPS J</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>1309</fpage>
            <page-range>1309-20</page-range>
            <pub-id pub-id-type="pmid">25274605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-&#x000c1;lvarez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sevilla-Llewellyn-Jones</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ag&#x000fc;era-Ortiz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic Drugs in Geriatric Psychopharmacology.</article-title>
            <source>Front Neurosci</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>1309</fpage>
            <pub-id pub-id-type="pmid">31866817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldenberg</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Pharmaceutical approval update.</article-title>
            <source>P T</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>198</fpage>
            <page-range>198-231</page-range>
            <pub-id pub-id-type="pmid">23785224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hilas</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Pharmacologic management of overactive bladder.</article-title>
            <source>Clin Interv Aging</source>
            <year>2007</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <page-range>337-45</page-range>
            <pub-id pub-id-type="pmid">18044184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reyes</surname>
                <given-names>JVM</given-names>
              </name>
              <name>
                <surname>Lieber</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin-Induced Hyperthermia in a Patient With Parkinson's Disease.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Apr</month>
            <day>26</day>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e14701</fpage>
            <pub-id pub-id-type="pmid">34055543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swana</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Youmans</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kogan</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bogetz</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Hallucinations after hypospadias repair.</article-title>
            <source>J Pediatr Surg</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>e33</fpage>
            <page-range>e33-5</page-range>
            <pub-id pub-id-type="pmid">16516613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26487.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <article-title>ACMT 2020 Annual Scientific Meeting Abstracts - New York, NY.</article-title>
            <source>J Med Toxicol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>21</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-168</page-range>
            <pub-id pub-id-type="pmid">32086766</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
